Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

On May 20, 2019 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, reported that the International Liver Cancer Association (ILCA) has accepted Can-Fite’s abstract describing the latest data from the Company’s Phase II Liver Cancer study of Namodenoson for an oral presentation at its annual conference (Press release, Can-Fite BioPharma, MAY 20, 2019, View Source [SID1234536467]). The oral presentation titled "The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled" will be delivered on September 22, 2019 during the Novel Targets and Prognostic Markers Session from 11:00 am to 12:30 pm. The ILCA’s 13th Annual Conference will take place from September 20 to 22, 2019 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ILCA is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines. Its mission is to lead a global community of physicians, scientists and allied professionals through education and research with the goal to better prevent and treat liver cancer.

"This is a very prestigious conference that brings together the leading thought leaders, researchers, and physicians in the treatment of liver cancer. Governing members of the ILCA thoroughly research each abstract submission and select those that are most relevant to the advancement of treating liver cancer. We are pleased that the selection committee sees the potential of Namodenoson as a treatment for advanced liver cancer patients with severe liver dysfunction. Based on both safety and efficacy in this Phase II study, Can-Fite is preparing a Phase III trial," stated Can-Fite CEO Pnina Fishman.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is being evaluated as a second line treatment for hepatocellular carcinoma, with a recently completed Phase II trial and planned Phase III trial in this indication. The drug is currently in an ongoing Phase II trial as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.